Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment Policymedical mutual - ohio Dawnzera Prior Auth Coverage…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy 2025

    Dawnzera (donidalorsen) coverage and prior authorization

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy 2025 alerts

    Get alerted when Policy 2025 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization, coverage criteria, dosing, duration, and site-of-care restrictions for Dawnzera (donidalorsen) for prevention of hereditary angioedema (HAE) for applicable Medical Mutual - Ohio members.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDawnzera (donidalorsen) coverage and prior authorization
    Policy CodePolicy Policy 2025
    Change TypeNo material change
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionPrior approval is required for Dawnzera when billed under the medical benefit using HCPCS J3490, J3590 or J9999.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12minimum age for covered indication
    80 mg q4wrecommended dosing (medical benefit)
    1 yrauthorization durations
    J3490/J3590/J9999codes requiring prior approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    non-hospital
    site-of-care restriction

    Coverage and Authorization Criteria

    Recommended Authorization Criteria for HAE prophylaxis

    Coverage is recommended for prophylaxis of HAE due to C1-INH deficiency in patients meeting diagnostic, prescriber, and response requirements.

    ANY of the following

    • Initial therapy (A)

      • Patient is ≥ 12 years of age
      • Diagnosis of HAE type I or type II confirmed by: functional C1-INH <50% of normal at baseline
      • Diagnosis confirmed by low serum C4 at baseline
      • Medication prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders
    • Currently receiving Dawnzera (B)

      • Patient has a diagnosis of HAE type I or type II
      • According to the prescriber, the patient has had a favorable clinical response since initiating Dawnzera prophylactic therapy compared with baseline (examples: decreased attack frequency, decreased attack severity, or decreased attack duration)
      • Medication prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders
    ref
    title
    ref]
    title

    Initial Therapy Requirements

    Initial approval is granted when ALL diagnostic and prescriber criteria are met and dosing conforms to medical benefit requirements.

    ALL of the following

    • Patient is ≥ 12 years of age
    • HAE type I or II confirmed with low functional C1-INH (<50% of normal) and low serum C4 at baseline
    • Medication prescribed by or in consultation with an allergist/immunologist or HAE specialist
    • Recommended dosing (medical benefit): 80 mg subcutaneously every 4 weeks (80 mg every 8 weeks may be considered)
    • Initial approval duration: 1 year

    Continuation / Extended Approval

    Continuation or renewal requires documented clinical benefit; approvals are issued for 1 year.

    ALL of the following

    • For patients currently receiving Dawnzera without prior approval through Coverage Review, evaluate under initial therapy criteria
    • Prescriber must attest to favorable clinical response compared to baseline (examples: decreased attack frequency, severity, or duration)
    • Extended approval duration: 1 year
    If the patient is currently receiving the requested therapy but has not previously received approval through the Coverage Review Department, review under criteria for Initial Therapy.

    Billing Codes and Coverage Status

    Medical benefit HCPCS codesHCPCSCovered
    J3490Unclassified drugs (when determined to be Dawnzera)
    J3590Unclassified biologics (when determined to be Dawnzera)
    J9999Unclassified antineoplastics (when determined to be Dawnzera)

    Prior Authorization, Documentation, and Site-of-Care

    Prior Authorization

    Prior approval required for Dawnzera billed under medical benefit

    Prior approval is required for Dawnzera when billed under the medical benefit using HCPCS J3490, J3590, or J9999. Prior approval requests that meet the policy criteria may be authorized by a nurse reviewer; requests that do not meet criteria will be forwarded to a qualified physician reviewer. Claims submitted with these HCPCS codes will pend with remark code M3M or M4M and be adjudicated per the Corporate Medical Policy.

    • Codes requiring prior approval: HCPCS J3490, J3590, J9999
    • Nurse reviewer may authorize if submitted documentation meets policy criteria
    • Requests not meeting criteria will be forwarded to a physician reviewer
    • Claims with these codes will pend with Remark Code M3M or M4M

    Drug and Diagnostic Definitions

    inv-06: Dawnzera (donidalorsen) — drug definition and indication summary
    Generic namedonidalorsen
    Brand nameDawnzera
    Class / mechanismPrekallikrein-directed antisense oligonucleotide
    Route / formulationSubcutaneous injection (single-dose autoinjector)
    IndicationProphylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥ 12 years of age
    inv-07: HAE type I/II diagnostic criteria — diagnostic lab thresholds
    Diagnostic requirement — functional C1-INH

    Dosing and Quantity

    inv-10: donidalorsen (Dawnzera) — quantity / dose (80 mg)
    Single-dose strength80 mg (0.8 mL) per autoinjector
    PresentationSterile, clear, colorless to yellow solution in a single-dose autoinjector
    Quantity limit (per month)80 mg per month (dosing interval typically every 4 weeks)

    Administration Location Guidance

    Note

    Site-of-care restriction for medical-benefit billing (non-hospital locations)

    For billing Dawnzera under the medical benefit, administer the drug only in non-hospital facility-based settings (such as home infusion, provider office, or free-standing ambulatory infusion center) unless the member qualifies for a site-of-care exception.

    • Applicable settings: home infusion provider, provider's office, free-standing ambulatory infusion center
    • If member meets site-of-care exception criteria, alternative settings may be allowed
    Policy Summary
    Payermedical mutual - ohio
    PolicyDawnzera (donidalorsen) coverage and prior authorization
    Policy CodePolicy Policy 2025
    Change TypeNo material change
    Effective DateNov 20, 2025
    Last ReviewNov 20, 2025
    Next Review DateNov 20, 2025
    Key ActionPrior approval is required for Dawnzera when billed under the medical benefit using HCPCS J3490, J3590 or J9999.
    SourceLink
    On This Page
    Coverage and Authorization CriteriaBilling Codes and Coverage StatusPrior Authorization, Documentation, and Site-of-CareDrug and Diagnostic DefinitionsDosing and QuantityAdministration Location Guidance
    Note: HAE with normal C1-INH (HAE type III) does NOT satisfy the diagnostic requirement for coverage.
    Billing Rule

    Restrict medical-benefit administration to non-hospital facility-based locations

    When Dawnzera is billed under the medical benefit, administration is restricted to non-hospital facility-based locations (for example: home infusion provider, provider's office, or free-standing ambulatory infusion center) unless the member meets site-of-care exception criteria.

    • Site-of-care restriction applies to initial and renewal requests
    • Exceptions permitted only if member meets the site-of-care exception criteria
    Documentation Required

    Provide requested clinical documentation to support medical necessity

    The Company may request additional documentation to support medical necessity and may deny reimbursement if the drug or services are not medically necessary, investigational, outside benefit scope, or if inappropriate/excessive billing is identified. Requested documentation may include patient records, test results, and provider credentials, and must be made available upon request.

    • Documentation may include patient records, test results, and provider ordering/performing credentials
    • Failure to provide requested documentation or determination of non-medical necessity may result in denial of reimbursement
    Functional C1-INH protein < 50% of normal at baseline (per laboratory reference values)
    Diagnostic requirement — serum C4Lower than normal serum C4 levels at baseline (per laboratory reference values)
    Excluded diagnosisHAE with normal C1-INH (HAE type III) does NOT satisfy the diagnostic requirement for coverage